Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
نویسندگان
چکیده
منابع مشابه
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
Introduction In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD). Consistent with its primary pharmacologic activity, tolvaptan use was commonly associated ...
متن کاملTolvaptan and Autosomal Dominant Polycystic Kidney Disease.
n engl j med 368;13 nejm.org march 28, 2013 1257 macrophage activation syndrome. In animals, high levels of interleukin-6 contribute to the triggering of this syndrome1; additional cytokines, including interferon-γ, interleukin-1, and interleukin-18, might be involved in maintaining and amplifying the inflammatory response.2 Indeed, interleukin-1 antagonism may be beneficial in a full-blown cas...
متن کاملEffect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
BACKGROUND and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 study demonstrated a significant beneficial effect of the vasopressin V2 receptor antagonist tolvaptan on rates of kidney growth and eGFR decline in autosomal dominant polycystic kidney disease (ADPKD). This post hoc analysis was performed to reassess th...
متن کاملCost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
UNLABELLED Chinese translation BACKGROUND In the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. OBJECTIVE To determine how the benefits of tolvaptan seen in TEMPO may relate to longer-term health outcomes, such as progression to...
متن کاملUrine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
The vasopressin-cAMP-osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopressin V2 receptor antagonist tolvaptan slowed ADPKD progression in patients with preserved GFR. H...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International Reports
سال: 2017
ISSN: 2468-0249
DOI: 10.1016/j.ekir.2017.07.004